arrow
R

Ravinder Anand

University of North Carolina Chapel Hill
H指数:37
被引数:4,738

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A remote intervention to improve medication nonadherence guided by a marker of risk derived from the electronic health records of adolescent transplant recipients.

基于青少年移植受者电子健康记录的风险标志物指导的远程干预以改善用药不依从性

2026-05-270
PRE
Population Pharmacokinetics and Exposure-Safety Analysis of Furosemide in Preterm Infants

呋塞米在早产儿中的群体药代动力学和暴露-安全性分析

2026-04-190
PRE
Correction: Population Pharmacokinetic Modeling of Oxcarbazepine and Its Active Metabolite 10‑Monohydroxy Derivative to Inform Dosing in Children with Obesity

更正:奥卡西平及其活性代谢物10-单羟基衍生物的群体药代动力学建模,以指导肥胖儿童用药剂量

2026-01-060
OAAI
Population Pharmacokinetic Modeling of Oxcarbazepine and Its Active Metabolite 10-Monohydroxy Derivative to Inform Dosing in Children with Obesity

奥卡沙比平及其活性代谢物10-单羟基衍生物的群体药代动力学建模,以指导肥胖儿童的剂量方案

2025-11-170
OAAI
Patient-Caregiver Discrepancy Score: Multisite Evaluation of a Novel Pediatric Outcome Measure

患者-照护者差异评分:一项多中心评估新型儿科结局指标的研究

2025-11-140
PRE
Corrigendum to “Furosemide Safety in Preterm Infants at Risk for Bronchopulmonary Dysplasia: A Randomized Clinical Trial” J Pediatr. 2025 Apr 28;283:114629

勘误:“Furosemide Safety in Preterm Infants at Risk for Bronchopulmonary Dysplasia: A Randomized Clinical Trial” J Pediatr. 2025 Apr 28;283:114629

2025-08-140
PRE
Lithium for the Maintenance Treatment of Bipolar I Disorder: A Double-Blind, Placebo-Controlled Discontinuation Study
2019-02-0124
OAAI